OSTEOproSPINE

Novel Bone Regeneration Drug Osteogrow: Therapeutic Solution for Lumbar Back Pain

Programme
Horizon 2020 & sub-programmes
Duration
66 months (January 2018 – June 2023)
Project funding
≈ €6 million
Project partners
12
Technology readiness level
0-2

What the project is about

OSTEOproSPINE aims to improve therapeutic options for patients suffering from degenerative disc diseases by translating the patient’s peripheral blood into extra-skeletal bone. The research will be based on a therapeutic system developed in the course of the previous research project OSTEOGROW, in which an autologous carrier and a biologically active human protein were combined to accelerate and enhance bone repair. For OSTEOproSPINE, the protein was reinforced with allograft. In the course of the project, the therapy will be tested in a Phase II clinical trial in four clinical centres.

Coordinator

Prof. Dr. Slobodan Vukicevic

University of Zagreb

Email coordinator

Your EURICE
contact

Your contact
Michaela Scheid
Senior Research & Impact Manager
E-mail

Explore THE COURT

Discover THE COURT, the EURICE environment where projects, expertise and partners connect across six innovation ecosystems.

Enter THE COURT